{"id":"https://openalex.org/W2809812205","doi":"https://doi.org/10.1161/circulationaha.118.035083","title":"Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus","display_name":"Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus","publication_year":2018,"publication_date":"2018-07-02","ids":{"openalex":"https://openalex.org/W2809812205","doi":"https://doi.org/10.1161/circulationaha.118.035083","mag":"2809812205","pmid":"https://pubmed.ncbi.nlm.nih.gov/29967228"},"language":"en","primary_location":{"id":"doi:10.1161/circulationaha.118.035083","doi":"https://doi.org/10.1161/circulationaha.118.035083","is_oa":false,"landing_page_url":"https://doi.org/10.1161/circulationaha.118.035083","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"},"volume":null,"type":"editorial","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078498803","display_name":"Naveed A. Sattar","orcid":"https://orcid.org/0000-0002-1604-2593","observed_orcids":["https://orcid.org/0000-0002-1604-2593"]},"institutions":[{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Naveed Sattar","raw_affiliation_strings":["Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (N.S.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (N.S.)","institution_ids":["https://openalex.org/I7882870"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071945904","display_name":"Darren K. McGuire","orcid":"https://orcid.org/0000-0002-6412-7989","observed_orcids":["https://orcid.org/0000-0002-6412-7989"]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Darren K. McGuire","raw_affiliation_strings":["University of Texas Southwestern Medical Center, Dallas (D.K.M.)","Darren K. McGuire University of Texas Southwestern Medical Center, Dallas (D.K.M.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas Southwestern Medical Center, Dallas (D.K.M.)","institution_ids":["https://openalex.org/I867280407"]},{"raw_affiliation_string":"Darren K. McGuire University of Texas Southwestern Medical Center, Dallas (D.K.M.)","institution_ids":["https://openalex.org/I867280407"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":55,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"138","issue":"1","first_page":"7","last_page":"9"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.003000000026077032,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.996999979019165},{"id":"https://openalex.org/keywords/cardiorenal-complications","display_name":"cardiorenal complications","score":0.9210000038146973},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.8529999852180481},{"id":"https://openalex.org/keywords/empagliflozin","display_name":"empagliflozin","score":0.9980000257492065},{"id":"https://openalex.org/keywords/canagliflozin","display_name":"canagliflozin","score":0.9419999718666077},{"id":"https://openalex.org/keywords/heart-failure","display_name":"heart failure","score":0.878000020980835},{"id":"https://openalex.org/keywords/cardiovascular-mortality","display_name":"cardiovascular mortality","score":0.8309999704360962},{"id":"https://openalex.org/keywords/kidney-disease","display_name":"kidney disease","score":0.6290000081062317},{"id":"https://openalex.org/keywords/atherosclerotic-cardiovascular-disease","display_name":"atherosclerotic cardiovascular disease","score":0.7850000262260437},{"id":"https://openalex.org/keywords/plasma-volume-reduction","display_name":"plasma volume reduction","score":0.703000009059906},{"id":"https://openalex.org/keywords/empa-reg-outcome","display_name":"EMPA-REG OUTCOME","score":0.6819999814033508},{"id":"https://openalex.org/keywords/canvas-trial","display_name":"CANVAS trial","score":0.7680000066757202},{"id":"https://openalex.org/keywords/pathophysiological-mechanisms","display_name":"pathophysiological mechanisms","score":0.5699999928474426},{"id":"https://openalex.org/keywords/cardiovascular-risk-reduction","display_name":"cardiovascular risk reduction","score":0.32600000500679016}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9545111656188965},{"id":"https://openalex.org/C2781309322","wikidata":"https://www.wikidata.org/wiki/Q5038718","display_name":"Cardiorenal syndrome","level":3,"score":0.769014835357666},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5988653302192688},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.515426754951477},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5004510879516602},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.45739421248435974},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4361470639705658},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.4093114137649536},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.36982035636901855},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3095497488975525}],"mesh":[{"descriptor_ui":"D000077203","descriptor_name":"Sodium-Glucose Transporter 2 Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D003928","descriptor_name":"Diabetic Nephropathies","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D003928","descriptor_name":"Diabetic Nephropathies","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D003928","descriptor_name":"Diabetic Nephropathies","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D006333","descriptor_name":"Heart Failure","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D006333","descriptor_name":"Heart Failure","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D006333","descriptor_name":"Heart Failure","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058065","descriptor_name":"Diabetic Cardiomyopathies","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D058065","descriptor_name":"Diabetic Cardiomyopathies","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D058065","descriptor_name":"Diabetic Cardiomyopathies","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D065840","descriptor_name":"Protective Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1161/circulationaha.118.035083","doi":"https://doi.org/10.1161/circulationaha.118.035083","is_oa":false,"landing_page_url":"https://doi.org/10.1161/circulationaha.118.035083","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"},{"id":"pmid:29967228","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29967228","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320322148","display_name":"Eisai","ror":"https://ror.org/04vvh7p27"},{"id":"https://openalex.org/F4320322436","display_name":"Novo Nordisk","ror":"https://ror.org/0435rc536"},{"id":"https://openalex.org/F4320331660","display_name":"Esperion Therapeutics","ror":"https://ror.org/019f2k932"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W2146264128","https://openalex.org/W2432507517","https://openalex.org/W2626446274","https://openalex.org/W2766617433","https://openalex.org/W2772204795"],"related_works":["https://openalex.org/W7046910106","https://openalex.org/W2546236920","https://openalex.org/W2585904003","https://openalex.org/W2616260093","https://openalex.org/W4233501496","https://openalex.org/W3205970331","https://openalex.org/W2990094817","https://openalex.org/W4243795743","https://openalex.org/W2602524134","https://openalex.org/W2551893511"],"abstract_inverted_index":{"ccasionally,":[0],"an":[1],"unexpected":[2],"clinical":[3],"trial":[4,24,263],"result":[5],"makes":[6],"us":[7,62],"reevaluate":[8],"what":[9],"we":[10,12],"think":[11],"know":[13],"about":[14],"pathogenic":[15],"pathways":[16,72,305],"linking":[17],"1":[18,51,230],"condition":[19],"to":[20,63,74,136,203,284,306,314,380,394],"another.The":[21],"EMPA-REG":[22,215],"OUTCOME":[23,216],"([Empagliflozin]":[25],"Cardiovascular":[26,266],"Outcome":[27],"Event":[28],"Trial":[29],"in":[30,106,157,175,243,260,373,401],"Type":[31],"2":[32,45,55,269],"Diabetes":[33],"Mellitus":[34],"Patients)":[35],"results":[36,232],"demonstrating":[37,218],"cardiovascular":[38,79,138,154,222,244,320],"and":[39,65,84,127,150,187,193,224,239,274,319,334,354,361,367],"kidney":[40,85,252],"benefits":[41,389],"with":[42,113,171,177,198,201,228,256,312,368,375,391],"the":[43,70,88,107,131,158,204,214,237,257,261,280,315,324,395,409],"type":[44],"diabetes":[46],"mellitus":[47],"(T2DM)":[48],"drug":[49],"empagliflozin,":[50],"a":[52,271,288,329],"sodium-glucose":[53],"cotransporter":[54],"inhibitor":[56],"(SGLT2i),":[57],"did":[58],"just":[59],"this.It":[60],"forced":[61],"reconsider":[64],"expand":[66],"our":[67,406],"notions":[68],"of":[69,91,183,206,241,291,317,323,332,345,357,364,408],"risk":[71,111,139,152,169,219,400],"leading":[73],"specific":[75],"T2DM":[76,92,114,134,159,178,402],"complications,":[77],"particularly":[78],"death,":[80],"heart":[81],"failure":[82],"(HF),":[83],"disease.For":[86],"decades,":[87],"cardiac":[89,346,352],"risks":[90],"had":[93],"been":[94],"selectively":[95],"focused":[96,162],"on":[97,164,209,251],"incremental":[98],"atherosclerotic":[99],"vascular":[100],"disease":[101],"(ASCVD)":[102],"risk.We":[103],"were":[104,233],"comfortable":[105],"knowledge":[108,397],"that":[109,341],"ASCVD":[110,149,165,168,210],"associated":[112,117],"stems":[115],"from":[116],"hypertension,":[118],"dyslipidemia,":[119],"hyperglycemia,":[120],"prothrombotic":[121],"tendencies,":[122],"insulin":[123],"resistance,":[124],"endothelial":[125],"dysfunction,":[126],"inflammatory":[128],"stress.Thus,":[129],"whenever":[130],"potential":[132,330],"for":[133,221,226,236],"drugs":[135],"mitigate":[137],"was":[140,143],"considered,":[141],"it":[142,369],"most":[144,234],"often":[145],"within":[146],"this":[147],"narrow":[148],"related":[151],"framework.Likewise,":[153],"outcomes":[155],"trials":[156],"field":[160],"have":[161,310,381,403],"primarily":[163],"outcomes.Certainly":[166],"lessening":[167],"matters,":[170],"substantial":[172],"successes":[173],"realized":[174],"patients":[176,374,378],"over":[179],"recent":[180],"decades-mostly":[181],"reductions":[182],"nonfatal":[184],"myocardial":[185,299,355],"infarction":[186],"stroke":[188],"risks-via":[189],"better":[190],"blood":[191],"pressure":[192],"low-density":[194],"lipoprotein":[195],"cholesterol":[196],"management,":[197],"less":[199],"certainty":[200],"regard":[202,313],"influence":[205],"glucose":[207],"lowering":[208],"risk.However,":[211],"then":[212],"came":[213],"results,":[217],"reduction":[220,242,338,344],"death":[223,321],"hospitalization":[225],"HF":[227,318,388,399],"empagliflozin.":[229],"These":[231],"surprising":[235],"speed":[238],"magnitude":[240],"risks,":[245],"as":[246,248],"well":[247],"favorable":[249],"effects":[250,340],"outcomes-findings":[253],"broadly":[254],"confirmed":[255],"SGLT2i":[258],"canagliflozin":[259],"CANVAS":[262],"program":[264],"(Canagliflozin":[265],"Assessment":[267],"Study).":[268],"As":[270],"result,":[272],"researchers":[273],"providers":[275],"alike":[276],"began":[277],"asking":[278],"how":[279],"SGLT2is":[281,392],"could":[282],"lead":[283],"such":[285],"benefits.HF":[286],"is":[287],"common":[289],"complication":[290],"T2DM,":[292,376],"now":[293],"occurring":[294],"more":[295],"frequently":[296],"than":[297],"incident":[298],"infarction,":[300],"thus":[301],"hinting":[302],"at":[303],"non-ASCVD":[304],"HF.Although":[307],"several":[308],"hypotheses":[309],"emerged":[311],"mechanism":[316],"benefit":[322],"SGLT2is,":[325],"indirect":[326],"evidence":[327],"suggests":[328],"role":[331],"modest":[333],"sustained":[335],"plasma":[336],"volume":[337,385],"via":[339],"likely":[342],"include":[343],"pre-and":[347],"afterload,":[348],"thereby":[349],"favorably":[350],"affecting":[351],"workload":[353],"energetics.Because":[356],"hyperglycemia-associated":[358],"glomerular":[359],"hyperfiltration":[360],"increased":[362],"reclamation":[363],"filtered":[365],"glucose,":[366],"sodium":[370],"by":[371],"SGTL2":[372],"these":[377],"tend":[379],"persistent":[382],"mild":[383],"intravascular":[384],"expansion.":[386],"3The":[387],"observed":[390],"added":[393],"existing":[396],"regarding":[398],"helped":[404],"reshape":[405],"understanding":[407],"patho-":[410]},"counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":13},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":2}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2018-07-10T00:00:00"}